The last five years has witnessed a remarkable evolution in the management of metastatic hormone-sensitive prostate cancer (mHSPC), with multiple agents demonstrating profound benefit in combination with initial androgen deprivation therapy (ADT). Historically, in a time when systemic therapy options were scarce, the responsibility of monitoring ADT efficacy fell squarely on urologists. As the disease progressed inevitably to the castration-resistant state, primary care would transition to medical oncologists, with urologists limited to providing interventional support for local complications on an as needed basis.
BJU international. 2019 Oct 29 [Epub ahead of print]
I A Thangasamy, E M Kwan, J Teh, N Sathianathen, O Alghazo, S Siva, A Azad, D G Murphy
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia., Department of Medicine, School of Clinical Sciences, Monash University, Australia., Division of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia., Department of Medical Oncology, Monash Health, Australia.